ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02270034
Recruitment Status : Recruiting
First Posted : October 21, 2014
Last Update Posted : March 16, 2018
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
Grupo Español de Investigación en Neurooncología

Brief Summary:
This multicenter, open-label, phase Ib trial aims to assess the safety and activity and safety of crizotinib (in combination with radiotherapy and temozolomide) in adult patients with newly diagnosed glioblastoma.

Condition or disease Intervention/treatment Phase
Glioblastoma Multiforme (Grade IV) of Cerebellum Drug: Crizotinib Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase Ib, Open-label, Multicenter, Dose-escalation Study Followed by an Extension Phase to Evaluate the Safety and Activity of the Combination of Crizotinib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma
Actual Study Start Date : August 13, 2014
Estimated Primary Completion Date : February 2019
Estimated Study Completion Date : February 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Cohort crizotinib
Combination of crizotinib with temozolomide and radiotherapy following Stupp regime
Drug: Crizotinib
Crizotinib is added to Stupp method




Primary Outcome Measures :
  1. Treatment safety [ Time Frame: 7 months ]
    Number of participants with adverse events as a measure of safety and tolerability


Secondary Outcome Measures :
  1. Recommended dose in phase II [ Time Frame: 7 months ]
    Based on pharmakinetic analysis by Cmax

  2. Anti-tumor activity [ Time Frame: 7 months ]
  3. Overall Survival [ Time Frame: Two years ]
    Time between start of treatment and death



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Ability to understand and the willingness to sign a written informed consent document.
  2. Male or Female ≥18 years old and ≤ 70 years old
  3. Newly diagnosed glioblastoma (GB) confirmed by biopsy or resection 4-7 weeks before registration.
  4. Patients must have at least 15 unstained slides or 1 tissue block (frozen or paraffin embedded) available from a prior biopsy or surgery (archival tumor material).
  5. Patients must have sufficient time for recovery from prior surgery (at least 4 weeks).
  6. Karnofsky Performance Score (KPS) ≥ 60%.
  7. Adequate hematologic function: Hemoglobin ≥ 10 g/dL, Leukocytes > 3,000/mcL, absolute neutrophil count (UNL) ≥ 1,500 cells/ul, platelets ≥ 100,000 cells/ul.
  8. Adequate liver function: Bilirubin ≤ 2 X upper limit of normal (ULN); aspartate aminotrasferase (AST) (SGOT) ≤ 2.5 X ULN
  9. Creatinine within normal institutional limits or creatinine clearance > 60 mL/min/1.73 m2l for subjects with creatinine levels above institutional normal.
  10. The effects of crizotinib on the developing human fetus are unknown. For this reason, women of child-bearing potential and men must agree to use adequate contraception (hormonal or harrier method of birth control; abstinence; surgical sterilization) prior to study entry and for the duration of study participation and for at least 3 months thereafter. The definition of effective contraception will be based on the judgment of the principal investigator or a designated associate. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. All female patients with reproductive potential must have a negative pregnancy test (serum/urine) within 2 weeks prior to starting treatment.

Exclusion Criteria:

  1. Presence of extra-cranial metastatic disease.
  2. Any prior radiotherapy (RT) or chemotheraphy (QT) treatment.
  3. Patients must not have received prior Gliadel wafers.
  4. The use of enzyme-inducing antiepileptic drugs will not be allowed. Those patients taking enzyme-inducing antiepileptic drugs required a 7-day washout period before registration.
  5. Any surgery (not including minor diagnostic procedures such as lymph node biopsy) within 2 weeks of baseline disease assessments; or not fully recovered from any side effects of previous procedures.
  6. Any clinically significant gastrointestinal abnormalities, which may impair intake, transit or absorption of the study drug, such as the inability to take oral medication in tablet form.
  7. Any psychiatric or cognitive disorder that would limit the understanding or rendering of informed consent and/or compromise compliance with the requirements of this protocol.
  8. Uncontrolled or significant cardiovascular disease, including:

    • A myocardial infarction within 12 months;
    • Uncontrolled angina within 6 months;
    • Congestive heart failure within 6 months;
    • Diagnosed or suspected congenital long QT syndrome;
    • Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or Torsades de pointes);
    • Prolonged corrected QT (QTc) interval on pre-entry electrocardiogram (>470 msec);
    • Any history of second or third degree heart block (may be eligible if currently have a pacemaker);
    • Heart rate <50/minute on pre-entry electrocardiogram;
    • Uncontrolled hypertension.
  9. Any patient with a history of significant cardiovascular disease, even if currently controlled, or who has signs or symptoms suggesting impaired left ventricular function in the judgment of the investigator must have a screening left ventricular ejection fraction (LVEF) evaluation by ECHO or angyography (MUGA). Patients with LVEF measurements below local institutional lower limit of normal or less than 50% will not be eligible.
  10. Individuals with a history of a different malignancy are ineligible except for the following circumstances: Individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancers are eligible if diagnosed and treated within the past 3 years: cervical cancer in situ, and basal cell or squamous cell carcinoma of the skin. Patients will not be eligible if they have evidence of other malignancy requiring therapy other than surgery within the last 3 years.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02270034


Contacts
Contact: Federico Nepote 0034 934 34 44 12 investigacion@mfar.net
Contact: Verónica Roca 0034 934 34 44 12 investigacion@mfar.net

Locations
Spain
Institut Català D'Oncologia L'Hospitalet (Ico) Recruiting
L'Hospitalet de Llobregat, Barcelona, Spain, 08908
Contact: Ana Márquez, Pharmacist    +34934344412    ana.marquez@mfar.net   
Principal Investigator: Miguel Gil, MD         
Hospital Del Mar Active, not recruiting
Barcelona, Spain, 08003
Hospital Clínic de Barcelona Recruiting
Barcelona, Spain, 08036
Contact: Ana Márquez, Pharmacist    +34 934344412    ana.marquez@mfar.net   
Principal Investigator: Estela Pineda, MD         
Hospital Universitario 12 de Octubre Recruiting
Madrid, Spain, 28041
Contact: Ana Márquez, Pharmacist    +934344412    ana.marquez@mfar.net   
Principal Investigator: Juan Sepulveda, MD         
Sponsors and Collaborators
Grupo Español de Investigación en Neurooncología
Pfizer
Investigators
Study Chair: Juan Manuel Sepúlveda, MD Hospital 12 de Octubre
Study Chair: María Martínez, MD Hospital del Mar

Responsible Party: Grupo Español de Investigación en Neurooncología
ClinicalTrials.gov Identifier: NCT02270034     History of Changes
Other Study ID Numbers: GEINO 1402
First Posted: October 21, 2014    Key Record Dates
Last Update Posted: March 16, 2018
Last Verified: March 2018

Additional relevant MeSH terms:
Glioblastoma
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Temozolomide
Crizotinib
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors